Bruker, which manufactures scientific instruments for molecular and materials research in addition to industrial and applied analysis, has inked a deal to purchase Oncovision’s pre-clinical imaging business. Oncovision develops medical imaging devices that can be used to diagnose cancer. Undisclosed at the time of the announcement were the financial terms of the agreement.
Oncovision will retain its clinical human imaging business, which includes the Mammi PET, a breast cancer diagnostic device that’s based on PET imaging. The acquisition, which is subject to closing conditions, is expected to close late in the fourth quarter of 2016.
“With this planned acquisition, Bruker expects to strengthen its expertise and leadership in pre-clinical imaging,” says Wulf I. Jung, president of Bruker’s pre-clinical imaging division. “The unique, performance-leading SiPM PET technology and products developed by Oncovision in close collaboration with the molecular imaging institute I3M and the University of Valencia, offer outstanding spatial resolution across the full field of view, increasing the high-resolution [field of view] by an order of magnitude compared to traditional PET systems, thereby facilitating quantitative imaging investigations.”
Ignasi Vivas, Oncovision’s CEO, shared the following: “Bruker is the undisputed leader in pre-clinical imaging with a unique portfolio of imaging modalities. Our pre-clinical team is delighted to join a company so well known for their innovation and dedication to excellence. The combined resources will accelerate the development and integration of our molecular imaging technologies, and fulfill the growing demand from translational scientists.”
For more information about this deal, visit Bruker.
